title: Tapentadol-ER for the treatment of diabetic peripheral neuropathy.
abstract: With the prevalence of diabetes mellitus (DM) increasing, pathologic complications such as diabetic peripheral neuropathy (DPN) are also becoming more common. Of those diagnosed with DM, 10% to 20% of patients suffer from painful DPN. Until recently, only pregabalin and duloxetine possessed Food and Drug Administration (FDA) approval for this condition. However, FDA recently approved tapentadol-ER [extended release] (Nucynta ER) for painful DPN. Tapentadol-ER is an opioid analgesic commonly used for the treatment of moderate-to-severe chronic pain that contains a unique dual mechanism acting as both a weak mu-opiod receptor agonist and norepinephine-reuptake inhibitor. It is by way of this unique dual mechanism that allows for effective analgesic effects with increased tolerability. This new FDA approval provides an additional therapeutic option to treat DPN in symptomatic patients.
authors.affiliation: Harrison School of Pharmacy, Auburn University, 1321 Walker Building (4201F), Auburn, AL 36849.
authors.forename: Gina
authors.initials: G
authors.lastname: Games
authors.forename: Amber
authors.initials: A
authors.lastname: Hutchison
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009638:Norepinephrine / Q000378:metabolism; D010636:Phenols / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017450:Receptors, Opioid, mu / Q000819:agonists; D000077432:Tapentadol; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010636:Phenols; D017450:Receptors, Opioid, mu; D000077432:Tapentadol; D009638:Norepinephrine
keywords: DM = Diabetes mellitus; DPN = Diabetic peripheral neuropathy; Diabetes mellitus; Diabetic peripheral neuropathy; ER = Extended release; Geriatric; MOR-NRI = mu-opiod receptor agonist-norepinephrine reuptake inhibitor; NRS = Numerical rating scale; Nucynta ER; SAE = Serious adverse event; SNRI = Serotonin-norepinephrine reuptake inhibitor; SSRI = Selective-serotonin reuptake inhibitor; TCA = Tricyclic antidepressant; TEAE = Treatment-emergent adverse event; Tapentadol ER